drugset / Trial / NCT04151706
CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML
Phase 2
Completed
7 enrolled
Robert Lowsky
National Cancer Institute (NCI) · collabNational Institutes of Health (NIH) · collab
NaSingle-groupOpen-labelTreatment
Summary
This study will evaluate combining stem cells from the patient's matched sibling donor (a standard CD34-selected transplant) with a second infusion of white blood cells called "CD8 memory T-cells" from their sibling donor.
Timeline
- Start
- 2020-02-27
- Primary completion
- 2023-09-08
- Completion
- 2023-09-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD8+ Memory T Cell Infusion | Cell therapy | — | — |
| Background | Busulfan | Small molecule | 6 mg/kg | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 60 mg/kg | Intravenous |
| Background | Fludarabine | Small molecule | 25 mg/m2 | Intravenous |
| Background | Thiotepa | Other / unclassified | 5 mg/kg | Intravenous |